Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Treatment period 1:To demonstrate that switching HD subjects with a baseline haemoglobin (Hb)
≥ 10 g/dL and ≤ 13 g/dL from either subcutaneous (SC) or intravenous (IV) rHuEPO to IV
darbepoetin alfa results in a mean Hb > 11 g/dL.
Treatment Period 2:To demonstrate that switching subjects with a Hb > 11 g/dL and ≤ 13 g/dL
from once weekly IV darbepoetin alfa to once every 2 weeks (Q2W) maintains the mean Hb at >
11 g/dL.